IDHC vs. VRCI, PRM, GENI, LLAI, DMTR, LLA, DXRX, AGL, YGEN, and ABDX
Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include Verici Dx (VRCI), Proteome Sciences (PRM), GENinCode (GENI), LungLife AI (LLAI), Deepmatter Group (DMTR), LLA.L,0P0001T9GN,0 (LLA), Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), and Abingdon Health (ABDX). These companies are all part of the "diagnostics & research" industry.
Integrated Diagnostics vs.
Integrated Diagnostics (LON:IDHC) and Verici Dx (LON:VRCI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Integrated Diagnostics has higher revenue and earnings than Verici Dx. Verici Dx is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.
43.0% of Integrated Diagnostics shares are owned by institutional investors. Comparatively, 51.9% of Verici Dx shares are owned by institutional investors. 34.0% of Integrated Diagnostics shares are owned by insiders. Comparatively, 17.1% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Integrated Diagnostics has a net margin of 17.21% compared to Verici Dx's net margin of -110.99%. Integrated Diagnostics' return on equity of 23.03% beat Verici Dx's return on equity.
In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.
Integrated Diagnostics received 56 more outperform votes than Verici Dx when rated by MarketBeat users.
Integrated Diagnostics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Verici Dx has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
Summary
Integrated Diagnostics beats Verici Dx on 9 of the 12 factors compared between the two stocks.
Get Integrated Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integrated Diagnostics Competitors List
Related Companies and Tools
This page (LON:IDHC) was last updated on 11/2/2024 by MarketBeat.com Staff
